Analysis of Marizyme, Inc. (MRZM)
Marizyme, Inc. is showing a stable price trend with the closing price consistently at $0.09 over the past few days. The Relative Strength Index (RSI) indicator is around 55.79, indicating a neutral market sentiment. The Moving Average Convergence Divergence (MACD) indicator is slightly positive, with the MACD line above the signal line and a positive MACD histogram.
Overall, Marizyme, Inc. seems to be in a consolidation phase with no significant price movements. Traders and investors may want to monitor the RSI and MACD indicators for potential changes in market sentiment and trend direction.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.
Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.
In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and price-to-book ratio, while the forward and trailing P/E ratios are moderate. The company's market capitalization and enterprise value are substantial, with a reasonable price-to-sales ratio.
The stock price summary includes beta, moving averages, and the range of prices over the past year. Dividends and splits information reveals the company's dividend history, payout ratio, and dividend yield metrics.
Overall, the data provides a comprehensive overview of the company's financial performance, stock metrics, valuation, stock price trends, and dividend policies.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:
1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to FY 2023, there was a consistent increase in revenue over the previous years.
- The highest revenue was recorded in FY 2022.
These trends indicate fluctuations in the company's revenue performance, with a notable decrease in the most recent fiscal year.
Revenue estimate
The analysts' estimates for the future quarterly and annual sales of the company indicate a moderate growth trend.
For the current quarter ending on June 30, 2024, the average estimate is $77,545,400,000, with a sales growth of 2% compared to the same period last year. The number of analysts providing estimates is 25.
Looking ahead to the next quarter ending on September 30, 2024, the average estimate increases to $85,501,800,000, with a sales growth of 3% compared to the previous year. Again, 25 analysts have contributed to these estimates.
For the current fiscal year ending on September 30, 2024, the average estimate for total sales is $357,772,000,000, showing a 1% growth from the previous year. The number of analysts providing estimates for the full year increases to 38.
In the following fiscal year ending on September 30, 2025, the average sales estimate rises to $380,772,000,000, indicating a more significant growth of 6% compared to the previous year. The number of analysts remains at 38.
Overall, the estimates suggest a steady growth trajectory for the company's sales in both the short term and the long term, with a slightly more optimistic outlook for the upcoming fiscal year.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:
1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is slightly higher at 5.2%.
3. Current Year: The growth rate for the current year is estimated to be 7.6%.
4. Next Year: The growth rate for the next year is expected to increase to 9.7%.
5. Past 5 Years (per annum): Over the past 5 years, the company has experienced a growth rate of approximately 20.1% per annum.
6. Next 5 Years (per annum): Looking ahead, analysts project a growth rate of around 9.7% per annum for the next 5 years.
Overall, it appears that the company is expected to maintain a steady growth trajectory, with a slight increase in growth rates for the upcoming periods compared to the current ones. However, the projected growth rates for the next year and the next 5 years are lower than the growth rate experienced in the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:
- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average forecast at $204.58. The current price of the security is $192.25, which is below the average and median forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
Balance Sheet
These are balance sheets. Here are the conclusions:
1. The total assets have been increasing over the years, reaching the highest value in 2023 at $352,755,000,000.
2. Current assets fluctuate from year to year, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2023 at $217,350,000,000.
4. Total liabilities have also been increasing, reaching the highest value in 2023 at $302,083,000,000.
5. Shareholders' equity has been fluctuating, with the highest value in 2019 at $90,488,000,000.
6. The company seems to be investing more in non-current assets over the years, which might indicate long-term growth strategies.
7. The company has been relying more on liabilities to finance its operations, as seen in the increasing total liabilities.
8. Shareholders' equity has not been growing at the same pace as total assets, indicating a potential need for better capital management.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:
1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance and payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability and variability, indicating a dynamic financial strategy.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:
1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests further growth compared to the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.MACD of MRZM